For nearly 15 years, the C5 inhibitors have been safely used in hospitals and the well-known function of C5a–C5aR in ARDS pathophysiology is indeed confirmed by their use in initial clinical trials. The gene discussed is C5; the disease is acute respiratory distress syndrome.